Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme – P4HA1 prolyl hydroxylase, is strongly induced in ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme – P4HA1 prolyl hydroxylase ...

The global anemia treatment market was valued at USD 10.0 billion in 2022 and is expected to grow to USD 14.9 billion by 2028 ...

Turkish drugmaker Er-Kim has signed a distribution agreement with Germany’s MEDICE Health Family to commercialize Vafseo ...

Vafseo ® (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to treat anemia due ...

Akebia has since engaged with the FDA on potentially expanding vadadustat treatment to this patient population and has received feedback on a protocol submitted for a Phase 3 cardiovascular outcome ...

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical ...

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

With the publication of this study, guselkumab is now the third IL-23 inhibitor to meet its primary efficacy endpoint in this population, joining the already approved mirikizumab and risankizumab. 3,4 ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...